SCHEMBL4094622

SCHEMBL4094622

COc1ccc(N2CCN(C)CC2)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)NCC(C)C)n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 16/20 0.62
▸ INSR P06213 8/20 0.62
▸ IGF1R P08069 6/20 0.62
▸ ZAP70 P43403 4/20 0.62
▸ EGFR P00533 3/20 0.62
▸ PLK4 O00444 2/20 0.62
▸ CHEK1 O14757 2/20 0.62
▸ AURKA O14965 2/20 0.62
▸ DCLK1 O15075 2/20 0.62
▸ PDPK1 O15530 2/20 0.62
▸ DAPK3 O43293 2/20 0.62
▸ JAK2 O60674 2/20 0.62
▸ ROCK2 O75116 2/20 0.62
▸ PRKD3 O94806 2/20 0.62
▸ MAP4K4 O95819 2/20 0.62
▸ PAK4 O96013 2/20 0.62
▸ CHEK2 O96017 2/20 0.62
▸ ERBB2 P04626 2/20 0.62
▸ NTRK1 P04629 2/20 0.62
▸ LCK P06239 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4099900 0.94 EGFR (0.70) ALKINSRIGF1RZAP70EGFR
SCHEMBL4089593 0.92 ZAP70 (0.68) ALKINSRIGF1RZAP70EGFR
SCHEMBL10207615 0.89 ALK (0.61) ALKINSRIGF1RZAP70EGFR
SCHEMBL4103316 0.88 ALK (0.64) ALKINSRIGF1RZAP70EGFR
SCHEMBL4100628 0.88 ALK (0.81) ALKINSRIGF1RZAP70EGFR
SCHEMBL4105756 0.87 ZAP70 (0.76) ALKINSRIGF1RZAP70EGFR
SCHEMBL4105766 0.87 ZAP70 (0.76) ALKINSRIGF1RZAP70EGFR
SCHEMBL12780216 0.86 ZAP70 (0.78) ALKINSRIGF1RZAP70EGFR
SCHEMBL12780186 0.86 ALK (0.62) ALKINSRZAP70
SCHEMBL12780351 0.86 ALK (0.62) ALKINSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131436-A1 Pyrimidine Derivatives NOVARTIS AG (CH) 2009-05-21 — — US claimed
EP-1784392-A2 PYRIMIDINE DERIVATIVES Novartis AG (CH) 2007-05-16 — — EP claimed
WO-2006021454-A2 PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2006-03-02 — — WO claimed
US-20090131436-A1 Pyrimidine Derivatives NOVARTIS AG (CH) 2009-05-21 — — US disclosed
EP-1784392-A2 PYRIMIDINE DERIVATIVES Novartis AG (CH) 2007-05-16 — — EP disclosed
WO-2006021454-A2 PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2006-03-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131436-A1 Pyrimidine Derivatives DPYD, TYMP, TYMS ALK 2060/4885INSR 2047/4885IGF1R 4608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback